Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | IGF1R | P08069 | 1/20 | 0.72 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.72 |
| ▸ | SYK | P43405 | 1/20 | 0.72 |
| ▸ | BMX | P51813 | 1/20 | 0.72 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.66 |
| ▸ | TUBB | P07437 | 1/20 | 0.66 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.66 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.66 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.66 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.66 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.66 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.66 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.66 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.66 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.66 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777942 | 0.89 | EGFR (0.80) | EGFRERBB4AURKALCKIGF1R | |
| SCHEMBL13777941 | 0.87 | KDR (0.81) | EGFRERBB4AURKALCKIGF1R | |
| SCHEMBL13777940 | 0.85 | EGFR (0.74) | EGFRERBB4AURKALCKIGF1R | |
| SCHEMBL13777945 | 0.85 | EGFR (0.74) | EGFRERBB4AURKALCKIGF1R | |
| SCHEMBL13777935 | 0.84 | EGFR (0.72) | EGFRERBB4AURKALCKIGF1R | |
| SCHEMBL13777946 | 0.84 | AURKA (1.00) | EGFRERBB4AURKALCKIGF1R | |
| Anilinopyrimidine1 SCHEMBL676556 | 0.84 | AURKA (1.00) | EGFRERBB4AURKALCKIGF1R | |
| SCHEMBL15625131 | 0.82 | TUBB4A (0.73) | EGFRERBB4AURKALCKIGF1R | |
| SCHEMBL1387447 | 0.81 | THRB (0.80) | EGFRERBB4AURKATHRBKDM4E | |
| SCHEMBL12431488 | 0.81 | EGFR (0.69) | EGFRERBB4BMXKDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | claimed |
| EP-2419110-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | Enzon Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| EP-2376087-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | Santaris Pharma A/S (DK) | 2011-10-19 | — | — | EP | claimed |
| CN-102223886-A | Erbb-3 (her3)-selective combination therapy | ENZON PHARMACEUTICALS INC | 2011-10-19 | — | — | CN | claimed |
| WO-2010120861-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ENZON PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| WO-2010054051-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | SANTARIS PHARMA A/S (DK) | 2010-05-14 | — | — | WO | claimed |
| EP-4578457-A1 | PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250197949-A1 | SYSTEMS AND METHODS FOR PREDICTING PROSTATE CANCER RECURRENCE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-19 | — | — | US | disclosed |
| CN-119768182-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-04 | — | — | CN | disclosed |
| US-20240309327-A1 | CARDIOMYOCYTE PRODUCTION METHOD | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-19 | — | — | US | disclosed |
| EP-4424819-A1 | METHOD FOR PRODUCING MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF | FUJIFILM Corporation (JP) | 2024-09-04 | — | — | EP | disclosed |
| US-20240277899-A1 | PRODUCTION METHOD OF MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF | FUJIFILM CORPORATION (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-2214486-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008157753-A1 | METHODS OF TREATMENT FOR SPINAL MUSCULAR ATROPHY | SMA FOUNDATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ERBB2, BMX, ERBB3 | EGFR 42/4885ERBB4 19/4885AURKA 43/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB4 1903/4885AURKA 1849/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB4 1903/4885AURKA 1849/4885 |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB4 4/4885AURKA 275/4885 |
| US-20240277899-A1 | PRODUCTION METHOD OF MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF | KIT, MYLK2, TNNT2 | EGFR 2160/4885ERBB4 1981/4885AURKA 747/4885 |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB4 4/4885AURKA 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.